The property was originally purchased in 2002 by Hall Gillespie from Lucent Technologies, Inc. for $27.5 million. The 100-acre site is situated just off Route 495 and is comprised of three buildings ranging in size from 100,000 sf to 200,000 sf as well as approvals to build another 500,000 sf of development. The development team had installed a multi-million dollar new entry road to the complex and was proceeding with a master plan for major building renovations.
Ian S. Gillespie, a partner at Hall Gillespie, tells GlobeSt.com that his firm had designed and priced a "fairly extensive" renovation on the campus when Boston Scientific approached with an offer. "We always saw this site as a premier corporate campus and were prepared to re-develop it ourselves," he says. "We are delighted that a company like Boston Scientific purchased this property and wants to utilize it for its own corporate campus. This transaction sends a very important message to the people of Massachusetts and the Metro West area that Boston Scientific, one of the region's great companies, has a strong commitment to grow in the area."
Gillespie tells GlobeSt.com the campus had been on the leasing market. Currently the buildings are nearly vacant with IQS occupying 7,500 sf and Stratus Corp. holding the lease for 26,300 sf. Stratus acquired the lease with a recent acquisition. But, Gillespie acknowledges, "We were prepared for a longtime hold, which we have done before."
In 1997, Gillespie and Hall purchased the 400,000-sf headquarters of GenRad Corp. at 300 Baker Ave. in Concord, MA for $6.3 million with Lehman Brothers of New York as their partner. After GenRad vacated the building, the developers renovated the property and immediately leased 180,000 sf to Lucent Technologies. Other tenants included SolidWorks, Mitsubishi, OneSource and EarthTech. In late 1999, the development team sold the fully-tenanted building and two building sites to Metropolitan Life Insurance Co. for $47.8 million.
Cushman & Wakefield of Massachusetts represented Hall Gillespie in the transaction while Trammell Crow represented Boston Scientific.
Want to continue reading?
Become a Free ALM Digital Reader.
Once you are an ALM Digital Member, you’ll receive:
- Breaking commercial real estate news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical coverage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
*May exclude premium content© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.